Background Many antihypertensive drugs (ADs) are photosensitizing, heightening reactivity of the skin to sunlight. Photosensitizing ADs have been associated with lip cancer, but whether they impact the risk of cutaneous squamous cell carcinoma (cSCC) is unknown. Objectives To examine the association between AD use and cSCC risk among a cohort of non-Hispanic white individuals with hypertension enrolled in a comprehensive integrated healthcare delivery system in northern California (n = 28 357). Methods Electronic pharmacy data were used to determine exposure to ADs, which were classified as photosensitizing, nonphotosensitizing or unknown, based on published literature. We identified patients who developed a cSCC during followup (n = 3010). We used Cox modelling to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). Covariates included age, sex, smoking, comorbidities, history of cSCC and actinic keratosis, survey year, healthcare utilization, length of health plan membership and history of photosensitizing AD use. Results Compared with nonuse of ADs, risk of cSCC was increased with ever having used photosensitizing ADs (aHR = 1Á17, 95% CI 1Á07-1Á28) and ever having used ADs of unknown photosensitizing potential (aHR = 1Á11, 95% CI 1Á02-1Á20), whereas no association was seen with ever having used nonphotosensitizing ADs (aHR = 0Á99; 95% CI 0Á91-1Á07). Additionally, there was a modest increased risk with an increased number of prescriptions for photosensitizing ADs (aHR = 1Á12, 95% CI 1Á02-1Á24; aHR = 1Á19, 95% CI 1Á06-1Á34; aHR = 1Á41, 95% CI 1Á20-1Á67 for one to seven, eight to 15 and ≥ 16 fills, respectively). Conclusions These findings provide moderate support for an increased cSCC risk among individuals treated with photosensitizing ADs.
• This study suggests that use of photosensitizing ADs is associated with a 17% higher risk of cSCC compared with nonuse of ADs.
• These results suggest that patients taking photosensitizing ADs may benefit from education on safe sun practices and closer screening for cSCC.
Many commonly used medications, including certain antihypertensive drugs (ADs), are photosensitizing, heightening reactivity of the skin to sunlight. [1] [2] [3] [4] [5] [6] [7] The photosensitizing properties of these medications are related to their distinct chemical structures that allow for the absorption of ultraviolet radiation (UVR). [7] [8] [9] [10] In the presence of UVR, photosensitizing medications may act as carcinogens by triggering phototoxic reactions, which cause acute DNA damage, and photoallergic reactions, which produce chronic inflammation. 8 Phototoxic reactions, which occur shortly after medication administration, result from radiation-induced production of reactive oxygen species. 8 Photoallergic reactions, which occur after a latent period of days to months, result from the radiation-induced formation of antigens that elicit a delayed T-cell-mediated hypersensitivity reaction. 8 The ensuing chronic inflammation may promote cutaneous carcinogenesis. 11 Given the association between UVR, DNA damage, chronic inflammation and development of cutaneous squamous cell carcinoma (cSCC), photosensitizing medications may increase cSCC risk. 12 A common malignancy with a rapidly rising incidence, cSCC is associated with substantial morbidity and cost. 13 Epidemiological data on the association between photosensitizing drug use and cSCC risk remain limited. Photosensitizing ADs have been associated with lip cancers, the majority of which are mucosal squamous cell carcinomas (SCCs). 14, 15 However, whether photosensitizing AD use affects cSCC risk is unclear. Previous observational studies have produced conflicting results, [16] [17] [18] [19] [20] [21] [22] [23] [24] and limitations have included small sample sizes, 22 reliance on self-reported medication history, 23 confounding by indication, incomplete capture of cases 19, 20, 24 and lack of pathological verification. 19, 20, 22, 24 In this study, we examined the association between AD use and cSCC risk among 28 357 non-Hispanic white (NHW) patients with hypertension in a closed healthcare system in northern California with integrated electronic pharmacy records and pathologically verified cSCC cases.
Patients and methods
The source population was the membership of Kaiser Permanente Northern California (KPNC). KPNC is a prepaid, integrated healthcare delivery system that serves approximately 4 million members. [1] [2] [3] [4] [5] [6] [7] Exposure was defined as two or more filled prescriptions for a given medication during the study period. While a single prescription for a photosensitizing AD could theoretically increase cSCC risk, two or more filled prescriptions were required to minimize the chance of including patients who filled a prescription but never took the medication. Drug exposure after baseline was treated as a time-varying covariate. Person-time from the start of follow-up until the first use of a given medication was classified as 'never use' for that medication. For the 'ever use' classification, once a patient met the exposure definition (two fills), he or she was considered exposed from that point forward, even if they later discontinued the medication. For exposure based on the number of prescriptions, once a patient met the criteria for a category of fills, he or she was considered exposed to that category until they met the criteria for the next higher category. We used Cox modelling to estimate hazard ratios (HRs) with 95% confidence intervals (CIs), associating AD use with cSCC. Nonusers of any ADs after cohort entry served as the reference group. We adjusted for variables associated with increased cSCC risk, including age, sex, smoking (current, former, never, unknown), comorbidities [Charlson Comorbidity Index (CCI) score 0, 1-2 or ≥ 3], history of cSCC and actinic keratosis (AK) and prior history of photosensitizing AD use (all in the 5 years prior to baseline). We also adjusted for survey year, length of KPNC health plan membership, baseline healthcare utilization and surveillance measure. Smoking history was based on self-report at cohort entry. CCI is a weighted score of 17 conditions that predicts the risk of 10-year mortality for patients with a range of these diagnosisbased comorbid conditions. 26 History of cSCC was determined from pathology reviews; history of AK was captured using ICD-9 code 702Á0; and prior photosensitizing AD use was determined based on pharmacy records. Healthcare utilization was defined as the average annual number of ambulatory visits in the 5 years prior to cohort entry, and the surveillance measure was defined as the average annual number of dermatology visits in the 5 years prior to cohort entry. All analyses were performed with SAS software version 9Á3 (SAS Institute, Cary, NC, U.S.A.) and all statistical tests were two-sided. This study was approved by the Institutional Review Board of the Kaiser Foundation Research Institute.
Results
We identified a cohort of 28 357 NHW members of the RPGEH with hypertension who were followed for a mean of 5Á09 years after cohort entry. Table 1 shows the baseline demographic characteristics of the cohort members.
The mean age at cohort entry was 69Á1 years (SD 10Á6 years) and was similar across the treatment groups. Women constituted 56Á3% of the cohort and 59Á5% of users of photosensitizing ADs. After baseline, 17 946 patients used photosensitizing ADs; 19 092 patients used nonphotosensitizing ADs; 17 345 patients used ADs with unknown photosensitizing potential; and 1530 patients did not use any ADs. There was considerable overlap between the treatment groups; many patients received prescriptions for multiple different classes of ADs after cohort entry. CCI score was higher among users of unknown photosensitizing ADs after cohort entry and lower among nonusers of ADs after cohort entry. Prior cSCC and AK were more common among nonusers of ADs after cohort entry (prior cSCC 14Á2%; prior AK 40Á1%) compared with the overall cohort (prior cSCC 7Á9%; prior AK 35Á2%). Prior photosensitizing AD use was less common among nonusers of ADs after cohort entry (51Á7%) compared with the overall cohort (74Á0%). We identified 3010 cSCCs over 144 215 person-years of follow-up. Table 2 summarizes the HRs for cSCC among those exposed to ADs compared with those with no AD use. Compared with nonuse of ADs, the adjusted hazard ratio (aHR) for ever use of photosensitizing ADs after baseline was 1Á17 (95% CI 1Á07-1Á28). The increase in cSCC risk associated with ever use of photosensitizing ADs was driven in large part by combination thiazide diuretics (aHR 1Á32, 95% CI 1Á19-1Á46). Alpha-2 receptor agonists (aHR 1Á30, 95% CI 0Á62-2Á74); potassium-sparing diuretics (aHR 1Á24, 95% CI 0Á96-1Á61); loop diuretics (aHR 1Á10, 95% CI 0Á98-1Á24); and thiazide diuretics (aHR 1Á09, 95% CI 0Á99-1Á19) all had HRs above 1Á0. The aHR for ever use of nonphotosensitizing ADs was 0Á99 (95% CI 0Á91-1Á07). Alpha blockers (aHR 0Á93, 95% CI 0Á83-1Á03), beta blockers (aHR 1Á04, 95% CI 0Á96-1Á12), central agonists (aHR 1Á07, 95% CI 0Á85-1Á34) and ARBs (aHR 0Á97, 95% CI 0Á87-1Á08) had HRs very close to 1Á0.
The aHR for ever use of ADs with unknown photosensitizing potential was 1Á11 (95% CI 1Á02-1Á20). The increase in cSCC risk associated with ever use of ADs with unknown photosensitizing potential was driven by ACE inhibitors (aHR 1Á10, 95% CI 1Á01-1Á19). CCBs had an HR very close to 1Á0 (aHR 1Á06, 95% CI 0Á98-1Á15). Vasodilators (aHR 0Á96, 95% CI 0Á76-1Á21) and other combinations (aHR 0Á81, 95% CI 0Á64-1Á03) were infrequently prescribed and not associated with increased cSCC risk. Table 3 summarizes dose-response analyses based on the number of prescriptions for ADs. There was a modest increase in the risk of cSCC with an increased number of prescriptions for photosensitizing ADs (one to seven fills aHR 1Á12, 95% CI 1Á02-1Á24; eight to 15 fills aHR 1Á19, 95% CI 1Á06-1Á34; ≥ 16 fills aHR 1Á41, 95% CI 1Á20-1Á67). In contrast, no dose-response relationship was observed with use of nonphotosensitizing ADs (one to seven fills: aHR 0Á99, 95% CI 0Á89-1Á09; eight to 15 fills aHR 1Á02, 95% CI 0Á92-1Á14; ≥ 16 fills aHR 0Á95, 95% CI 0Á83-1Á07) or ADs of unknown photosensitizing potential (one to seven fills aHR 1Á12, 95% CI 1Á02-1Á23; eight to 15 fills aHR 1Á12, 95% CI 1Á01-1Á25; ≥ 16 fills aHR 1Á06 95% CI 0Á93-1Á21).
Consistent with the main results, when outcomes were restricted to invasive disease, users of photosensitizing ADs had a very modest increased risk of invasive cSCC compared with nonusers (aHR 1Á14, 95% CI 1Á02-1Á27); users of ADs in the 'unknown' photosensitizing category also had a very modest increased risk of invasive cSCC (aHR 1Á08, 95% CI 0Á99-1Á19). In contrast, users of nonphotosensitizing ADs had a very modest decreased risk of invasive cSCC (aHR 0Á92, 95% CI 0Á84-1Á02).
The association of photosensitizing ADs with risk of cSCC did not vary by history of actinic lesions (aHR 1Á16, 95% CI 1Á05-1Á28 among those with history; aHR 1Á17, 95% CI 0Á97-1Á41 among those without history). There was an increased risk of cSCC among users of ADs in the 'unknown' photosensitizing category with a past history of actinic lesions (aHR 1Á15, 95% CI 1Á05-1Á26), but not among those without a past history of actinic lesions (aHR 0Á99, 95% CI 0Á84-1Á16). Table 4 summarizes the results of additional subgroup analyses of new users of ADs after cohort entry and nonusers of photosensitizing ADs before cohort entry. Analyses of new users of ADs after cohort entry were inconclusive because of the small number of new users (n = 405). Compared with nonuse of ADs, new users of photosensitizing ADs had an elevated cSCC risk (aHR 1Á46, 95% CI 0Á70-3Á02), new users of nonphotosensitizing ADs had a reduced cSCC risk (aHR 0Á49, 95% CI 0Á19-1Á30) and risk for new users of ADs with unknown photosensitizing potential fell between photosensitizing and nonphotosensitizing new users (aHR 0Á92, 95% CI 0Á42-2Á00). Owing to the small number of new users, we were unable to demonstrate statistically significant differences in cSCC risk for the different exposure categories. Analyses restricted to individuals without use of photosensitizing ADs prior to baseline (n = 7363) showed that users of photosensitizing ADs and ADs with unknown photosensitizing potential during follow-up had an increased cSCC risk compared with users of nonphotosensitizing ADs during followup, although the results were not statistically significant (use of photosensitizing ADs during follow-up: aHR 1Á20, 95% CI 0Á97-1Á48; use of ADs with unknown photosensitizing potential during follow-up: aHR 1Á16, 95% CI 0Á97-1Á39).
Discussion
In this large cohort study conducted in a community-based comprehensive integrated healthcare delivery system, we found a 17% increase in risk of cSCC in NHW patients with hypertension who received photosensitizing ADs during follow-up compared with nonusers of ADs. Each class of photosensitizing AD showed small increases in risk, but combination thiazide diuretics were the only class to attain statistical significance. In addition, there was a modest increase in risk with increasing number of prescriptions of photosensitizing ADs. Risk of cSCC was increased among users of photosensitizing ADs regardless of history of actinic lesions. Use of ADs with unknown photosensitizing potential was associated with a statistically significant 11% increase in risk and nonphotosensitizing ADs were not associated with increased risk of cSCC. Findings among new users of these drugs were generally consistent with those of all users, but statistical significance was not evident owing to the small number of new users.
Results of previous studies of ADs and the risk of skin cancer have been inconsistent. [17] [18] [19] [20] [21] [22] [23] [24] While some have shown increased risk with the use of potassium-sparing and combination diuretics, 19, 24 but not loop or thiazide diuretics, 19, 20, 24 several studies, including one at KPNC, have shown a significant association between thiazide diuretic use and increased SCC risk. 14,15,18,22 ACE inhibitors and ARBs have been associated with a reduced risk of keratinocyte cancers in some studies 17, 21 and an increased risk in others. 22, 24 Beta blockers, which are not widely recognized as photosensitizing, [1] [2] [3] [4] [5] have been associated with an increased risk of lip cancer and SCC in some studies. 14, 20 To our knowledge, the present study is the first to examine cSCC risk associated with the use of alpha blockers and central agonists. A recent meta-analysis of observational studies examining the use of ADs and risk of keratinocyte carcinoma found that diuretics are associated with increased SCC risk, while ACE inhibitors and ARBs are associated with decreased SCC risk in high-risk individuals, and CCBs and beta blockers are not associated with SCC risk. 27 The chemical structures of photosensitizing drugs permit the absorption of UVR, [8] [9] [10] the primary risk factor for SCC. 28 They promote sunburn and may be carcinogenic, triggering phototoxic or photoallergic reactions. 8 These effects, in turn, may induce DNA damage and chronic inflammation. Observed differences is cSCC risk among various photosensitizing drugs may be due to differences in their biological effects and differences in study design. Treatment groups are not mutually exclusive. Patients may contribute to multiple treatment groups owing to receipt of prescriptions for more than one AD. Therefore, these counts do not add up to the overall number of patients.
Strengths of this study include its setting in a comprehensive healthcare system with unified electronic patient records that allowed ascertainment of physicians' diagnosis of hypertension, pathological verification of the diagnosis of cSCC, and documentation of dispensing of the pharmaceutical drugs studied, thus eliminating the possibility of recall bias in patients. We were also able to document and attempt to account for healthcare utilization as possibly influencing our findings.
However, the main associations that we observed, although statistically significant, were quite small in magnitude and could have been affected by the study's limitations. Although we adjusted for several baseline characteristics, residual confounding could have affected our findings. We were unable to adjust for sun exposure but could ascertain and control for prior AKs, which may be viewed as risk factors for cSCC that were related to sun exposure. Although drug-related acute adverse reactions to sunlight could influence the choice of ADs or lead to a change of AD, it seems unlikely that this would have a major effect on our findings or that differences in sun exposure would be related to which ADs are prescribed. While our use of prescriptions filled at KPNC pharmacies as a surrogate for medication use could have led to exposure misclassification, it is unlikely that those with pharmacy benefits would have filled their prescriptions elsewhere. There was considerable overlap between the treatment groups, and concurrent use of ADs from multiple different classes after cohort entry may have influenced the cSCC risk observed in each treatment group.
In conclusion, we observed a modest association between increasing exposure to photosensitizing ADs and increasing risk of cSCC. Additional studies, including those that control for potential confounding factors, such as sun exposure, are needed to confirm our findings and further evaluate the risks associated with specific drug classes. In the meantime, patients taking photosensitizing ADs may benefit from education on safe sun practices and closer screening for cSCC given the potential public health implications associated with widespread use of these common medications.
